Last reviewed · How we verify
Anascorp
Anascorp, developed by Instituto Bioclon S.A. de C.V., is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and lack of direct competitors. The primary risk is the potential for generic entry post-patent expiry in 2028.
At a glance
| Generic name | Anascorp |
|---|---|
| Also known as | Antivenin Centruroides (scorpion) equine immune F(ab')2 |
| Sponsor | Instituto Bioclon S.A. de C.V. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation (PHASE3)
- Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation (PHASE3)
- Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients (PHASE2, PHASE3)
- Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anascorp CI brief — competitive landscape report
- Anascorp updates RSS · CI watch RSS
- Instituto Bioclon S.A. de C.V. portfolio CI